Agilent and akoya biosciences announce partnership to drive multiplex tissue assay development for biopharma applications

Santa clara, calif, & marlborough, mass.--( business wire )--agilent technologies, inc. (nyse: a) today announced a partnership with akoya biosciences, inc. (nasdaq: akya), the spatial biology company®, to develop multiplex-immunohistochemistry diagnostic solutions for tissue analysis and to commercialize workflow solutions for multiplex assays in the clinical research market. integrating agilent's dako omnis (autostaining instrument) and akoya's phenoimager® ht (imaging platform) for multiplex chromogenic immunohistochemistry (mihc) and immunofluorescent (mif) assays will create a singular end-to-end commercial workflow, including reagents, staining, imaging, and analysis.
A Ratings Summary
A Quant Ranking